Kairos Pharma, Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.9M
- Price
- $0.29
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.73%
- Volume
- 297.6K
About
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Quick stats
Shares outstanding23.7M
Computed float13.4M
Float / shares56.7%
Cash runway (months)5.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001962011
Websitehttps://kairospharma.com
AI Summary
AI-generated1/25
standardbearishreverse split
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Kairos Pharma announced a 1-for-7 reverse stock split effective September 1, 2026, intended to reduce outstanding shares and maintain compliance with NYSE American listing requirements.
The split will automatically combine every seven shares into one, with no fractional shares issued and a new CUSIP number 48301N203 assigned to the post-split common stock.
Outstanding convertible notes, warrants, and equity awards will be proportionally adjusted to reflect the new ratio, while the par value remains $0.001 per share.
Red flags
- Reverse stock split signals listing compliance risk